ClinicalTrials.gg
RecruitingNCT07195071FOCUSUpdated Oct 21, 2026

Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening

An observational study in Hereditary Cancer Syndrome, sponsored by Columbia University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Columbia University · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 21, 2026Eligibility revisedDesign changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Neoplastic Syndromes, Hereditary with a site in United States — 19 open to participants now, 21 under way, none of them phase 3. Neoplastic Syndromes, Hereditary · United States.

Planned enrollment
8th of 15
1,000 · median 1,000
Started
2026
with 3 others
Observational
15 of 33
8 open now
Primary completion
2027-12
later than 6 of 18 live
Registered
31st of 33
by date
Lead sponsor
2 of 33
Columbia University

Among the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2026, is one of 15 observational ones, reaches primary completion later than 6 of the 18 other live ones, and was the 31st registered.

Neoplastic Syndromes, Hereditary

47 studies on the registry are indexed under Neoplastic Syndromes, Hereditary; 26 are open to participants now.

Browse Neoplastic Syndromes, Hereditary studies →

Open to participants now

19 of the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Neoplastic Syndromes, Hereditary studies recruiting now, 11 (55%) set no upper age limit and 6 (30%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 55 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, or all of them as a file.
02

Study summary

The investigators hypothesize that preconception and pregnancy may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal care or preconception care. The goal is to evaluate the acceptability of hereditary cancer testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention

Read the detailed description

In this prospective trial, a clinician in the department of OBGYN will meet with preconception/pregnant patients who are undergoing obstetrical carrier screening (OCS) at Columbia University affiliated OBGYN clinics to review the options for concurrent hereditary cancer screening (HCS). If interested in the study, the patient will be contacted by a study coordinator and offered participation in the study. The patients will have counseling on potential risks and benefits of genetics testing and have OCS performed per standard of care protocols. This consultation will include collection of comprehensive personal and family history to generate a cancer genetic risk assessment. The patient will be counseled based on their cancer genetic risk assessment, whether or not National Comprehensive Cancer Network (NCCN) guidelines for cancer risk assessment are met and the resulting anticipated cost. The patient will be offered additional consultation with a genetic counselor and/or a Natera financial representative if desired for further counseling. If the patient decides to proceed with HCS, the Natera Empower Hereditary Cancer Panel will be drawn at the time of the OCS panel blood draw and sent to Natera for processing. OCS results will be sent separately and reported to the patient based on standard protocols. Patients that have HCS panels sent will be notified of their results by a genetic counselor from Columbia University's Department of OBGYN and standard of care post test counseling/referrals made.

The study team will evaluate patient acceptance of testing and the patient experience, via validated surveys conducted at time of testing. The study team will evaluate if patient sociodemographic characteristic (e.g. age, parity, race, ethnicity, medical history, family history) are associated with patient acceptance of the combined OCS/HSC panel. Patients that elect to undergo HCS panel will also complete the Regret About Healthcare Decisions Survey after receiving their HCS results. Participation in surveys is encouraged but not mandatory. All patient demographics, survey screens and results will be stored in a secure online database maintained by Columbia University's Department of OBGYN. This data will be entered and maintained by study personal at Columbia University. Patients enrolled in the study will be invited to participate in an interview conducted by telephone at times convenient for them. Interviews will be conducted by language-concordant, trained qualitative experts. Interviews will be recorded and transcribed. Participation in the interview is not mandatory.

Patients that completed HCS and had a mutation that resulted in a recommendation for clinical follow up (e.g. BRCA 1/2 mutation with recommendation for breast screening) will be contacted by telephone at 18 months and asked whether they completed the medical follow-up prompted by HCS results. Participation in this follow-up is not mandatory.

03

Conditions studied

  • Hereditary Cancer Syndrome

Keywords

  • obstetrical carrier screening
  • Pregnant women
  • prenatal screening
  • carrier screening
  • genetic testing
  • hereditary cancer
  • hereditary cancer genetic testing
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients receiving expanded carrier screening at OBGYN clinics

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 years - 55 years
  • Patients receiving obstetrical-related care at a CUMC-affiliated enrollment site
  • Patients who have elected to undergo OCS with the CUMC-affiliated obstetrics provider
  • Patients with prior OCS but planned to repeat OCS are eligible
  • Patients can speak and read in English or Spanish

Exclusion criteria

Exclusion criteria:

  • Patients who have previously completed a multigene hereditary cancer syndrome panel
  • Patients that have a hematologic cancer or hematologic pre-cancer
  • Patients who have a history of an bone marrow transplant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Arm A: Hereditary cancer testing

    Hereditary Cancer screenings testing and Obstetric Cancer Screening

    Device: Natera empower comprehensive hereditary cancer panel · Device: Obstetrical carrier screening

  • Arm B: No hereditary caner testing

    Obstetric Cancer screening test only

    Device: Obstetrical carrier screening

Interventions

  • DeviceNatera empower comprehensive hereditary cancer panel

    Natera Empower Comprehensive Hereditary Cancer Panel to screen for hereditary cancers

  • DeviceObstetrical carrier screening

    Obstetrical carrier screening for genetic conditions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Complete Both HCS and OCS

    The percent of patients who complete hereditary cancer screening (HCS) when offered in addition to routine obstetrical carrier screening (OCS) during preconception and obstetrical-related care.

    Time frame: Approximately at the end of recruitment, expected at 2 years

Secondary outcomes

  1. Score on Regret About Healthcare Decisions survey

    Participant experience with combined HCS and OCS will be assessed using a validated Regret About Healthcare Decisions Survey. The minimum score is 0 (lowest regret) to 100 (highest regret).

    Time frame: 2 to 6 months after enrollment

  2. Score on Regret About Healthcare Decisions Survey among pregnant participants

    Assessment of participant experience with combined OCS and HCS in pregnant participants using Regret About Healthcare Decisions Survey and qualitative interviews. The minimum score is 0 (lowest regret) to 100 (highest regret).

    Time frame: Approximately at the end of recruitment, expected at 2 years

  3. Score on Regret About Healthcare Decisions Survey among nonpregnant participants

    Assessment of participant experience with combined OCS and HCS in nonpregnant participants using Regret About Healthcare Decisions Survey and qualitative interviews. The minimum score is 0 (lowest regret) to 100 (highest regret).

    Time frame: Approximately at the end of recruitment, expected at 2 years

  4. Hereditary cancer screening results

    Number of pathologic variants identified by hereditary cancer screening.

    Time frame: Approximately at the end of recruitment, expected at 2 years

  5. Percentage of High-Risk Participants Utilizing Guideline-Based Cancer Mitigation Strategies

    Among participants who complete both HCS and OCS and are identified as being at elevated cancer risk, this measure captures the percentage who undergo one or more guideline-based cancer mitigation strategies, such as mammogram, breast MRI, or colonoscopy.

    Time frame: 18 months after enrollment

  6. Percentage of Participants Who Complete Both HCS and OCS during pregnancy

    The percent of patients who complete hereditary cancer screening (HCS) when offered in addition to routine obstetrical carrier screening (OCS) while pregnant.

    Time frame: Approximately at the end of recruitment, expected at 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2025
First posted
Sep 26, 2025
StartActual
Feb 12, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Revised
Oct 21, 2026
Design
Study type Interventional→Observational
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Eligibility Revised
    Design Study type Interventional→Observational
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07195071
Collaborators
Natera, Inc.
Responsible party
Shayan M. Dioun (Assistant Professor of Obstetrics and Gynecology, Division of Gynecologic Oncology, Columbia University) — Principal investigator
First posted
Sep 26, 2025
Start date
Feb 12, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Jessica Giordano
Contact
jlg2197@cumc.columbia.edu
212-305-7250
Reena Vattakalam
Contact
rmv2110@cumc.columbia.edu
212-342-6895
Shayan Dioun, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion